Security key
221015100
Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS)
CUSIP: 221015100
Q2 2017 13F Holders as of 30 Jun 2017
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 17,504,516
- Total 13F value
- $211,804,598
- Share change
- +169,419
- SEC-reported price per share
- $12.10
- Number of holders
- 48
- Value change
- -$2,803,453
- Number of buys
- 34
- Number of sells
- 22
- Shares outstanding
- 91,091,040
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2017
Institutions
48
Top holders
10
CRVS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2017
Previous quarter: Q1 2017
Corvus Pharmaceuticals, Inc. SEC filings
Corvus Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 221015100
Recent filing periods:
Ownership snapshot
Top reported holders of CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Mar 2017
13F
Lead comparable stake: 5.9%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 5.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
5.9%
Novo Holdings A/S
3.5%
ADAMS STREET PARTNERS LLC
3%
FMR LLC
2.3%
PRICE T ROWE ASSOCIATES INC /MD/
0.87%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
5.9%
|
$111,729,000
5,379,349 shares
|
— | 31 Mar 2017 |
| Novo Holdings A/S |
13F
Company
|
3.5%
|
$66,963,000
3,224,046 shares
|
— | 31 Mar 2017 |
| ADAMS STREET PARTNERS LLC |
13F
Company
|
3%
|
$55,817,000
2,687,381 shares
|
— | 31 Mar 2017 |
| FMR LLC |
13F
Company
|
2.3%
|
$44,097,000
2,123,106 shares
|
— | 31 Mar 2017 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
0.87%
|
$16,520,000
795,396 shares
|
— | 31 Mar 2017 |
| JENNISON ASSOCIATES LLC |
13F
Company
|
0.6%
|
$11,296,000
543,849 shares
|
— | 31 Mar 2017 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2017
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
48
Shares
17,504,516
Rows available
48
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2017 vs Q1 2017 Across Filers
Q1 2017 holders
52
Q2 2017 holders
48
Holder diff
-4
| Investor | Q1 2017 Shares | Q2 2017 Shares | Share Diff | Share Chg % | Q1 2017 value | Q2 2017 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend